CliffBio
biologic

Enspryng

satralizumab-mwge

Loss of exclusivityAugust 2032projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameEnspryng
Active ingredientsatralizumab-mwge
Strength120MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalAugust 2020
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.